Maze Therapeutics, Inc.
MAZE
Rank in Stocks
#6020
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops... Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Share Price
$34.91
Last synced: 2026-11-09
Market Cap
$1.94B
Change (1 day)
2.11%
Change (1 year)
9.64%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Maze Therapeutics, Inc. (MAZE)
Category
Healthcare
EPS for Maze Therapeutics, Inc. (MAZE)
EPS as of June 2026 TTM: $-2.74
According to Maze Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-2.74. At the end of 2025 the company had an EPS of $-3.05, a decrease compared to its 2024 EPS of $0.08.
EPS history for Maze Therapeutics, Inc. from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.74 | -10.16% |
| 2025 | $-3.05 | -4,020.31% |
| 2024 | $0.08 | -103.39% |
| 2023 | $-2.29 | -12.64% |
| 2022 | $-2.63 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -671.53% |
US
|
|
| $-7.07 | 158.03% |
US
|
|
| $-5.29 | 93.07% |
AU
|
|
| $12.88 | -570.08% |
BE
|
|
| $21.56 | -886.86% |
NL
|
Questions about Maze Therapeutics, Inc.'s earnings per share (EPS)
What is Maze Therapeutics, Inc.'s earnings per share (EPS)?
Maze Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-2.74, as of Jun 2026.
What was Maze Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Maze Therapeutics, Inc.'s earnings per share (EPS) was $-3.05, compared with $0.08 in 2024.
How has Maze Therapeutics, Inc.'s earnings per share (EPS) changed since 2022?
From 2022 to 2025, Maze Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($0.08) and lowest in 2025 ($-3.05).
How does Maze Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Maze Therapeutics, Inc.'s earnings per share (EPS) ($-2.74) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.